Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Andrew W. Drake"'
Autor:
SJ J. Diong, Aarti Jashnani, Andrew W. Drake, Christine Bee, Felix Findeisen, Gavin Dollinger, Feng Wang, Arvind Rajpal, Pavel Strop, Peter S. Lee
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTThe clinical successes of immune checkpoint blockade have invigorated efforts to activate T cell-mediated responses against cancer. Targeting members of the PVR family, consisting of inhibitory receptors TIGIT, CD96, and CD112R, has been an a
Externí odkaz:
https://doaj.org/article/a87135d2ea7c4bbf994e640a49d231a7
Autor:
Haibin Chen, Christine Bee, Ginger Rakestraw, Arvind Rajpal, Matthew Tomlinson, Flavio Schwarz, Gabriel Wu, Pavel Strop, Michael Hornsby, Andrew W. Drake, Zimple Matharu, Gavin Dollinger
Publikováno v:
Analytical Chemistry. 93:16474-16480
Identification of antibodies targeting diverse functional epitopes on an antigen is highly crucial for discovering effective therapeutic candidates. Employing a traditional stepwise antibody "screening funnel" as well as prioritizing affinity-based s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d239b88bb49bb94e4143df02bdb52ca7
https://doi.org/10.1021/acs.analchem.1c03548
https://doi.org/10.1021/acs.analchem.1c03548
Autor:
Andrew W. Drake, Scott L. Klakamp
Publikováno v:
Journal of Pharmaceutical Sciences. 110:2585-2589
Because the authors continue to note instances in the scientific literature of failure to use the correct receptor binding site concentration for determining binding constants, herein we discuss the fundamental concepts that need to be considered to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::351ed3ca686a567f966e94a435a3358c
https://doi.org/10.1016/j.xphs.2021.03.026
https://doi.org/10.1016/j.xphs.2021.03.026
Autor:
Gady Cojocaru, Margaret L. Tang, Patrick Wall, Sandeep Kumar, Eran Ophir, Hsin-Yuan Cheng, John J. Hunter, Ling Leung, Andrew W. Drake, Maya F. Kotturi, Masha Frenkel, Kathryn Logronio, David Bernados, Moran Galperin, Kyle Hansen, Spencer Liang, Samir Qurashi, Mark A. White, Zoya Alteber, Sarah Whelan
Publikováno v:
Cancer Immunology, Immunotherapy. 70:3525-3540
Immune checkpoint inhibitors (ICIs) have emerged as promising therapies for the treatment of cancer. However, existing ICIs, namely PD-(L)1 and CTLA-4 inhibitors, generate durable responses only in a subset of patients. TIGIT is a co-inhibitory recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3956f7736390726882c24308715f5566
https://doi.org/10.1007/s00262-021-02921-8
https://doi.org/10.1007/s00262-021-02921-8
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e51964 (2012)
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the epidermal growth factor family and has a variety of physiological and pathological functions. Modulation of HB-EGF activity might have a therapeutic potential in t
Externí odkaz:
https://doaj.org/article/c6b8267b4c4640fba1db816f1a6c3ba5
Autor:
Giuseppe A. Papalia, Margaret L. Tang, Mary Haak-Frendscho, Andrew W. Drake, Scott L. Klakamp, Gregory Landes
Publikováno v:
Analytical Biochemistry. 429:58-69
To characterize a proprietary therapeutic monoclonal antibody (mAb) candidate, a rigorous biophysical study consisting of 53 Biacore and kinetic exclusion assay (KinExA) experiments was undertaken on the therapeutic mAb complexing with its target ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9ea5aafa9629d59bdb8fb0544110c4b
https://doi.org/10.1016/j.ab.2012.06.024
https://doi.org/10.1016/j.ab.2012.06.024
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 12, p e51964 (2012)
PLoS ONE, Vol 7, Iss 12, p e51964 (2012)
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the epidermal growth factor family and has a variety of physiological and pathological functions. Modulation of HB-EGF activity might have a therapeutic potential in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fba056c17b5043b5a0244f7dc714d2e0
https://pubmed.ncbi.nlm.nih.gov/23251664
https://pubmed.ncbi.nlm.nih.gov/23251664
Autor:
Giuseppe A. Papalia, Andrew W. Drake
Publikováno v:
Development of Antibody-Based Therapeutics ISBN: 9781441959539
Development of therapeutic monoclonal antibodies (mAbs) requires rigorous measurements of the kinetic and thermodynamic binding properties of antibody–antigen complexes for drug candidate optimization and the design of clinical dosing strategies. F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ad18c23a35f57239773bce1e658063d
https://doi.org/10.1007/978-1-4419-5955-3_5
https://doi.org/10.1007/978-1-4419-5955-3_5
Autor:
Andrew W. Drake, Scott L. Klakamp
Publikováno v:
Journal of immunological methods. 371(1-2)
Determining the optimal conditions for surface regeneration is fundamental for performance of efficient and robust protein-protein interaction kinetic studies. We devised a systematic methodology comprised of an automated seven-cycle analyte and buff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f99c78d1e4af3f087469663611ba6a81
https://pubmed.ncbi.nlm.nih.gov/21703275
https://pubmed.ncbi.nlm.nih.gov/21703275
Publikováno v:
Current Trends in Monoclonal Antibody Development and Manufacturing ISBN: 9780387766423
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7346998cca7ddb1e8099926144e59631
https://doi.org/10.1007/978-0-387-76643-0_11
https://doi.org/10.1007/978-0-387-76643-0_11